GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genor Biopharma Holdings Ltd (HKSE:06998) » Definitions » PB Ratio

Genor Biopharma Holdings (HKSE:06998) PB Ratio : 0.50 (As of Jun. 03, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Genor Biopharma Holdings PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-06-03), Genor Biopharma Holdings's share price is HK$1.29. Genor Biopharma Holdings's Book Value per Share for the quarter that ended in Dec. 2023 was HK$2.56. Hence, Genor Biopharma Holdings's PB Ratio of today is 0.50.

The historical rank and industry rank for Genor Biopharma Holdings's PB Ratio or its related term are showing as below:

HKSE:06998' s PB Ratio Range Over the Past 10 Years
Min: 0.22   Med: 0.54   Max: 55.03
Current: 0.5

During the past 6 years, Genor Biopharma Holdings's highest PB Ratio was 55.03. The lowest was 0.22. And the median was 0.54.

HKSE:06998's PB Ratio is ranked better than
93.3% of 1313 companies
in the Biotechnology industry
Industry Median: 2.52 vs HKSE:06998: 0.50

During the past 12 months, Genor Biopharma Holdings's average Book Value Per Share Growth Rate was -35.70% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -31.00% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 23.20% per year.

During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Genor Biopharma Holdings was 98.80% per year. The lowest was -31.00% per year. And the median was 46.10% per year.

Back to Basics: PB Ratio


Genor Biopharma Holdings PB Ratio Historical Data

The historical data trend for Genor Biopharma Holdings's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genor Biopharma Holdings PB Ratio Chart

Genor Biopharma Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial - 2.55 1.20 0.67 0.46

Genor Biopharma Holdings Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.20 0.87 0.67 0.56 0.46

Competitive Comparison of Genor Biopharma Holdings's PB Ratio

For the Biotechnology subindustry, Genor Biopharma Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genor Biopharma Holdings's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genor Biopharma Holdings's PB Ratio distribution charts can be found below:

* The bar in red indicates where Genor Biopharma Holdings's PB Ratio falls into.



Genor Biopharma Holdings PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Genor Biopharma Holdings's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=1.29/2.562
=0.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Genor Biopharma Holdings  (HKSE:06998) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Genor Biopharma Holdings PB Ratio Related Terms

Thank you for viewing the detailed overview of Genor Biopharma Holdings's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Genor Biopharma Holdings (HKSE:06998) Business Description

Traded in Other Exchanges
Address
1690 Zhangheng Road, Building 3, Pudong New District, Shanghai, CHN, 201203
Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates include GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), a novel PD-1 mAb drug candidate; GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL mAb drug candidate.
Executives
Hillhouse Investment Management, Ltd. 2102 Investment manager
Hhjh Holdings Limited 2101 Beneficial owner
Hillhouse Fund Iv, L.p. 2201 Interest of corporation controlled by you
Hh Bio Investment Fund, L.p. 2201 Interest of corporation controlled by you
Hillhouse Capital Management, Ltd. 2102 Investment manager
Hh Bio Investment Fund L.p. 2201 Interest of corporation controlled by you
Temasek Capital (private) Limited
Aranda Investments Pte. Ltd.
Seletar Investments Pte Ltd
Walga Biotechnology Limited 2101 Beneficial owner
Shang Hai Wo Jia Sheng Wu Ji Shu You Xian Gong Si 2201 Interest of corporation controlled by you
Yun Nan Wo Sen Sheng Wu Ji Shu Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Temasek Holdings (private) Limited

Genor Biopharma Holdings (HKSE:06998) Headlines

No Headlines